Kcentra [Prothrombin Complex Concentrate (Human)]

Kcentra is indicated for the emergency reversal of acquired clotting factor deficiency induced by vitamin K antagonist therapy in adult patients with acute major bleeding.

Pearl of the day medication: Kcentra [Prothrombin Complex Concentrate (Human)]

Indication: Kcentra [prothrombin complex concentrate (human)]is indicated for the emergency reversal of acquired clotting factor deficiency induced by vitamin K antagonist therapy (eg, warfarin) in adult patients with acute major bleeding.

Insight:

  • Dosage: 20 to 50 units/kg, not to exceed 2500 to 5000 units.
  • Dosage forms: Kcentra is available in a single-use vial containing coagulation factors II, VII, IX and X, and antithrombotic proteins C and S in the form of a lyophilized concentrate.
  • Adverse events: The most common adverse reactions (frequency ≥ 2.8%) observed in subjects receiving Kcentra were headache, nausea/vomiting, arthralgia and hypotension.
  • Action mechanism: Kcentra contains vitamin K-dependent coagulation factors II (FII), VII (FVII), IX (FIX) and X (FX), collectively known as the prothrombin complex, as well as protein C and protein S antithrombotics. If the patient has acquired clotting factor deficiency where one or more of the vitamin K-dependent clotting factors are deficient, bleeding may occur.

Source: Kcentra Product Labeling (fda.gov)

Comments are closed.